Drug Overview

Selonsertib is an investigational medication being studied for its ability to treat serious inflammatory and fibrotic diseases. It is a laboratory-made molecule designed to stop specific stress signals inside cells that lead to organ scarring and cell death.

While it has been tested in several large-scale clinical trials, it is currently not available for general prescription. It is primarily accessed through participation in approved medical research studies.

• Generic name: Selonsertib (also known as GS-4997)
• US Brand names: None (Investigational drug)
• Drug Class: ASK1 inhibitor, Small molecule inhibitor
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Selonsertib is a Targeted Therapy and a Smart Drug. It is designed to act on a very specific protein that only becomes a problem when cells are under extreme stress or are sick.

At the molecular level, selonsertib works by blocking a protein called Apoptosis Signal-regulating Kinase 1, or ASK1. In a healthy body, ASK1 helps cells respond to stress. However, in diseases like cancer or liver scarring, ASK1 becomes overactive due to oxidative stress (damage from harmful oxygen molecules).

When ASK1 is too active, it triggers a chain reaction through two main communication pathways: the p38 MAPK pathway and the JNK pathway. These signals tell the cell to do three harmful things:

1. Apoptosis: The cell is forced to kill itself.
2. Inflammation: The cell releases chemicals that cause swelling and pain.
3. Fibrosis: The cell starts building tough, scarred tissue (like a permanent internal scab).

Selonsertib binds directly to the part of the ASK1 protein that starts this chain reaction. By “turning off” ASK1, the drug stops the p38 and JNK signals. This prevents the organ from building more scar tissue and allows healthy cells to survive longer.

FDA-Approved Clinical Indications

Because selonsertib is an investigational drug, it does not have official FDA-approved indications yet. However, it has been studied extensively for the following conditions:

Oncological uses

• Investigational treatment for advanced solid tumors (studied in combination with other therapies).
• Investigational research into preventing cancer-related organ damage.

Non-oncological

• Nonalcoholic Steatohepatitis (NASH), a severe form of fatty liver disease with scarring.
• Diabetic Kidney Disease (Diabetic Nephropathy).
• Primary Sclerosing Cholangitis (a chronic bile duct disease).

Dosage and Administration Protocols

In clinical trials, selonsertib is given as a daily pill. The exact dose depends on the specific trial protocol and the condition being treated.

Dose Adjustments

There are no established dose adjustment rules for patients with renal (kidney) or hepatic (liver) insufficiency outside of trial protocols. However, because the drug is processed by the liver and filtered by the kidneys, doctors monitor these organs closely. If organ function drops significantly, the drug is usually paused.

Clinical Efficacy and Research Results

Research results from 2020 to 2025 have provided a clearer picture of how selonsertib performs in real patients.

In the STELLAR Phase 3 clinical trials, researchers looked at whether selonsertib could reverse advanced liver scarring (cirrhosis). The results showed that while the drug was very safe, it did not significantly meet the primary goal of improving liver scarring by at least one stage without the disease getting worse. For example, in the trial for Stage 3 fibrosis, about 10 percent to 15 percent of patients saw improvement, which was similar to the group taking the placebo.

However, researchers are still analyzing numerical data regarding its effect on kidney disease. In Phase 2 trials for diabetic kidney disease, patients taking 10 milligrams of selonsertib daily showed a slower decline in the “estimated glomerular filtration rate” (a measure of kidney health) after the first 48 weeks of treatment. This suggests the drug might help protect kidneys over a long period.

Safety Profile and Side Effects

Selonsertib is generally considered to be well-tolerated with a manageable safety profile.

Black Box Warning

There is no Black Box Warning for selonsertib because it is not yet an FDA-approved medication.

Common side effects

These side effects are seen in greater than 10 percent of patients:

• Headache
• Nausea
• Feeling very tired (fatigue)
• Upper respiratory tract infections (like a common cold)

Serious adverse events

• Significant increases in liver enzymes (a sign of liver stress)
• Sudden worsening of kidney function
• Potential for heart rhythm changes (monitored via EKG)

Management strategies

Most common side effects like headaches or nausea are mild and can be managed with standard over-the-counter medications. However, because the drug acts on the liver and kidneys, patients must have blood tests every few weeks. If liver enzymes (like ALT or AST) rise to three times the normal limit, the medical team will stop the drug to protect the organ.

Research Areas

Selonsertib is a major focus in regenerative medicine research. Scientists are studying how blocking ASK1 can help protect “progenitor cells” (the body’s natural repair cells). In liver and kidney diseases, these repair cells are often killed off by the ASK1 pathway. By using selonsertib to keep these cells alive, researchers hope to encourage the body to naturally regrow healthy organ tissue rather than just building scar tissue. It is also being studied alongside immunotherapy to see if it can reduce the “oxidative stress” that often prevents the immune system from attacking tumors effectively.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• A complete liver function panel (ALT, AST, Bilirubin).
• A kidney function test (Serum Creatinine and GFR).
• An EKG to check baseline heart rhythm.
• A biopsy or specialized scan (like a FibroScan) to measure existing organ scarring.

Precautions during treatment

Patients must be careful when taking other medications. Selonsertib can interact with certain drugs used for cholesterol or blood pressure. Regular blood draws are mandatory to ensure the drug is not causing silent damage to the liver or kidneys.

Do’s and Don’ts list

• Do take your pill at the same time every day to keep the drug levels steady.
• Do report any yellowing of the skin or eyes (jaundice) immediately.
• Do stay hydrated to help your kidneys process the medication.
• Don’t stop taking the medicine suddenly without talking to your research doctor.
• Don’t take herbal supplements like St. John’s Wort, which can interfere with how the drug works.
• Don’t ignore new or worsening swelling in your legs or feet.

Legal Disclaimer

This guide is for informational purposes only and does not serve as medical advice. Selonsertib is an investigational drug and is not approved by the FDA for the treatment of any disease. Always speak with your doctor or a qualified oncology specialist before starting any new treatment or joining a clinical trial.